EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biological evaluation of a glucose‐based boron carrier as a potential agent for boron neutron capture therapy

Surachet Imlimthan iD, Katayun Bahrami iD, Henna Pehkonen iD, Alessia Centanni iD, Ahmed B Montaser iD, Arina Värä iD, Jelena Matović iD, Heidi Liljenbäck iD, Tatsiana Auchynnikava iD, Kristiina M Huttunen iD, Anne Roivainen iD, Anu J Airaksinen iD und 4 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.70054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Surachet Imlimthan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Boron Neutron Capture Therapy, Glucose, Head and Neck Neoplasms, Boron Compounds. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Syöpäsäätiö, Jane ja Aatos Erkon Säätiö, Ruth och and Nils-Erik Stenbäcks Stiftelse Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Boron neutron capture therapy (BNCT) is an innovative radiation oncology approach that targets tumors selectively, minimizing damage to healthy tissues through high‐linear‐energy‐transfer particles released during the boron neutron capture reaction. Current boron carriers like sodium mercaptoundecahydrododecaborate (BSH) and L‐ p ‐boronophenylalanine (BPA) face limitations in specificity and solubility. Our recently developed 6‐ O ‐( o ‐carboranylmethyl)‐ d ‐glucopyranose (B‐Glc) shows promise as an alternative, demonstrating strong interactions with glucose transporters in human head and neck squamous cell carcinoma (HNSCC) CAL 27 cells in vitro. This study aims to extend in vitro investigations to three additional patient‐derived human HNSCC cell lines (UT‐SCC‐14, UT‐SCC‐28, and UT‐SCC‐42B) and to further evaluate in vivo pharmacokinetics in selected HNSCC tumor xenografts. The B‐Glc showed superior uptake and favorable kinetic parameters compared to BPA and BSH in all tested cell lines. Initial positron emission tomography imaging using [ 18 F]fluoro‐2‐deoxy‐ d ‐glucose ([ 18 F]FDG) radiotracer confirmed increased glucose uptake in CAL 27 and UT‐SCC‐14 tumors in vivo, supported by glucose transporter 1 (GLUT1) expression observed in tumor section immunohistochemistry. Biodistribution studies of the B‐Glc (75 mg/kg dose) revealed no significant impact of blood glucose levels on tumor uptake, with peak boron accumulation at 15–30 min post‐injection, comparable uptake to the clinical BPA‐fructose complex (400 mg/kg dose) performance at 60 min, achieving the required tumor boron concentration (>20 ppm) for effective BNCT. Overall, this study underscores an advancement in targeted BNCT, highlighting B‐Glc as an effective GLUT1‐targeting carrier for enhanced therapeutic outcome in HNSCC and the potential to use [ 18 F]FDG as a companion diagnostic for the glucoconjugate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron Neutron Capture TherapyGlucoseHead and Neck NeoplasmsBoron CompoundsCarcinoma, Squamous CellBoronHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysSquamous Cell Carcinoma of Head and NeckMice, NudeTissue DistributionFemaleGlucose Transporter Type 1Positron-Emission Tomography

Stichwörter der Autor:innen

BNCTGLUT1boron delivery agentsboron neutron capture therapydrug deliveryglucoconjugateglucose transporter 1

Substanzen

GlucoseBoron CompoundsBoronGlucose Transporter Type 1

Autor:innen und Institutionen

  • Department of Chemistry, University of Helsinki, Helsinki, Finland.
  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
  • Turku PET Centre and Turku Center for Disease Modeling, University of Turku, Turku, Finland.
  • Turku PET Centre and Department of Chemistry, University of Turku, Turku, Finland.
  • Applied Tumor Genomics Research Program and Department of Oncology, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

ORCID-Profile: Surachet Imlimthan, Katayun Bahrami, Henna Pehkonen, Alessia Centanni, Ahmed B Montaser, Arina Värä, Jelena Matović, Heidi Liljenbäck, Tatsiana Auchynnikava, Kristiina M Huttunen, Anne Roivainen, Anu J Airaksinen, Filip S Ekholm, Outi Monni, Jarkko Rautio, Mirkka Sarparanta

Förderung

  • Syöpäsäätiö
  • Jane ja Aatos Erkon Säätiö
  • Ruth och and Nils-Erik Stenbäcks Stiftelse Foundation
  • Päivikki ja Sakari Sohlbergin Säätiö
  • Alfred Kordelinin Säätiö
  • Academy of Finland

Zitieren

APA

Imlimthan, S., Bahrami, K., Pehkonen, H., Centanni, A., Montaser, A. B., Värä, A., Matović, J., Liljenbäck, H., Auchynnikava, T., Huttunen, K. M., Roivainen, A., Airaksinen, A. J., Ekholm, F. S., Monni, O., Rautio, J., & Sarparanta, M. (2025). Biological evaluation of a glucose‐based boron carrier as a potential agent for boron neutron capture therapy. International Journal of Cancer. https://doi.org/10.1002/ijc.70054

Vancouver

Imlimthan S, Bahrami K, Pehkonen H, Centanni A, Montaser AB, Värä A, et al. Biological evaluation of a glucose‐based boron carrier as a potential agent for boron neutron capture therapy. International Journal of Cancer. 2025. doi:10.1002/ijc.70054

BibTeX
@article{Imlimthan2025,
  author = {Imlimthan, Surachet and Bahrami, Katayun and Pehkonen, Henna and Centanni, Alessia and Montaser, Ahmed B and Värä, Arina and Matović, Jelena and Liljenbäck, Heidi and Auchynnikava, Tatsiana and Huttunen, Kristiina M and Roivainen, Anne and Airaksinen, Anu J and Ekholm, Filip S and Monni, Outi and Rautio, Jarkko and Sarparanta, Mirkka},
  title = {Biological evaluation of a glucose‐based boron carrier as a potential agent for boron neutron capture therapy},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.70054}
}
Kostenlos starten →